Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. (Q38884347)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

0 references

1 reference

title

Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Mohammad Karamouzian

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

Andrew Stewart

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Steve Kanters

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Alaa Hamed

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Jeroen Jansen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Keith Chan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Antonio Toscano

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

2 July 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

264

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

621-630

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27372449%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00415-016-8219-8

17 March 2020

exact match

0 references

cites work

Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Prevalence of lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Disease severity in children and adults with Pompe disease related to age and disease duration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Consensus treatment recommendations for late-onset Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

A randomized study of alglucosidase alfa in late-onset Pompe's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

The impact of antibodies in late-onset Pompe disease: a case series and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Progress in Enzyme Replacement Therapy in Glycogen Storage Disease Type II

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease—a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: a 2-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8219-8

Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II

21 January 2018

1 reference

12 December 2020

Clinical features of late-onset Pompe disease: a prospective cohort study

1 reference

12 December 2020

Course of disability and respiratory function in untreated late-onset Pompe disease

1 reference

12 December 2020

Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy

1 reference

12 December 2020

Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease

1 reference

12 December 2020

Enzyme replacement therapy and fatigue in adults with Pompe disease

1 reference

12 December 2020